Quest Diagnostics Inc (DGX) - Wednesday, Jul 23, 2025

Key points (machine generated)

• Quest Diagnostics is a leading diagnostic health information provider in the U.S. with projected revenues of $9.9 billion in 2024, increasing to $11.2 billion by 2026.
• The company operates in a duopoly with LabCorp, granting it significant pricing power despite challenges like high fixed costs and complex reimbursement processes.
• Quest's focus on dividends and share repurchases indicates strong investment appeal and potential for sustained profitability.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.